Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.

Biotechnology

Cue Biopharma

Dan Passeri

Siddhartha Shrivastava

Andrey Antov

Matteo Levisetti

Steven Quayle

Peter Sheridan

Natasha Girgis

James Murray

Colin Sandercock

Kerri-Ann Millar

Anish Suri

Research and Development Team

Legal and Regulatory Affairs

Advisory Team

Finance and Operations

Leadership Team

Teams at Cue Biopharma

Research and Development Team

Legal and Regulatory Affairs

Advisory Team

Finance and Operations

Leadership Team